4.7 Article

Lost in translation: returning germline genetic results in genome-scale cancer research

期刊

GENOME MEDICINE
卷 9, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s13073-017-0430-4

关键词

Genomic data; Return of results; Research ethics; Whole-genome sequencing

资金

  1. National Health and Medical Research Council of Australia (NHMRC) [631701, 535903, 427601, 1112113]
  2. Queensland Government (NIRAP)
  3. University of Queensland
  4. Institute for Molecular Bioscience
  5. ustralian Government: Department of Innovation, Industry, Science and Research (DIISR)
  6. Cancer Council NSW [SRP06-01, SRP11-01. ICGC]
  7. Cancer Institute NSW [10/ECF/2-26, 06/ECF/1-24, 09/CDF/2-40, 07/CDF/1-03, 10/CRF/1-01, 08/RSA/1-15, 07/CDF/1-28, 10/CDF/2-26, 10/FRL/2-03, 06/RSA/1-05, 09/RIG/1-02, 10/TPG/1-04, 11/REG/1-10, 11/CDF/3-26, 13ECF1-46, 13/CDF/1-01]
  8. Garvan Institute of Medical Research
  9. Avner Nahmani Pancreatic Cancer Foundation
  10. Jane Hemstritch in memory of Philip Hemstritch
  11. National Health and Medical Research Council of Australia [1112113] Funding Source: NHMRC
  12. MRC [MR/N005813/1] Funding Source: UKRI
  13. Cancer Research UK [22533, 23526] Funding Source: researchfish
  14. Medical Research Council [MR/N005813/1] Funding Source: researchfish
  15. Pancreatic Cancer UK [FLF2015_04_Glasgow] Funding Source: researchfish

向作者/读者索取更多资源

Background: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. Methods: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium-high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. Results: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. Conclusion: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据